Lakefront Biotherapeutics (GLPGF) Raw Materials (2021 - 2025)

Lakefront Biotherapeutics (GLPGF) has reported Raw Materials for 5 consecutive years, with $26.2 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Raw Materials fell 52.14% year-over-year to $26.2 million in Q4 2025; TTM through Dec 2025 was $26.2 million, a 52.14% decrease from a year earlier, with the FY2025 full-year figure at $25.4 million, down 54.13% from the prior year.
• Raw Materials was $26.2 million for Q4 2025 at Lakefront Biotherapeutics, down from $54.7 million in the prior quarter.
• Over five years, Raw Materials peaked at $59.5 million in Q4 2023 and troughed at $16.4 million in Q4 2021.
• A 5-year average of $39.3 million and a median of $39.9 million in 2022 frame the typical range for Raw Materials.
• Across the five-year window, Raw Materials surged 142.81% in 2022 and slumped 52.14% in 2025, its largest moves.
• Over 5 years, Raw Materials stood at $16.4 million in 2021, then surged by 142.81% to $39.9 million in 2022, then jumped by 49.16% to $59.5 million in 2023, then fell by 8.0% to $54.7 million in 2024, then tumbled by 52.14% to $26.2 million in 2025.
• The last three Raw Materials figures came in at $26.2 million (Q4 2025), $54.7 million (Q4 2024), and $59.5 million (Q4 2023), per Business Quant data.